



## Scientific Advisory Board

### **Prof. Hanns Möhler, Chairman**

Prof. Möhler is Director of the Institute of Pharmacology and Toxicology at the Swiss Federal Institute of Technology and is one of the most distinguished scientists in the field of neuropharmacology. He has extensive experience in the pharmaceutical industry and was Vice-Director of Science at Hoffmann-La Roche. Prof. Möhler contributes valuable advice to Affectis in the field of genetic control of behaviour and the mechanisms regulating emotions, cognition and memory.

### **Prof. Florian Holsboer, founder**

Prof. Holsboer is Director of the Max-Planck Institute of Psychiatry in Munich. As founder of Affectis, he brings precious counsel regarding the clinical aspects of depression and will play a vital role in designing the clinical trials.

### **Prof. Nick Barden, co-founder**

Prof. Barden is Director of the Neuroscience Research Unit at the University of Laval in Quebec, Canada. He has been investigating various populations of bipolar and depressed patients for more than 18 years. He not only contributes new targets to Affectis, but also advises the company in the field of human genetics and population studies.

### **Prof. Wolfgang Wurst, co-founder**

Prof. Wurst is head of the Institute of Developmental Genetics at the National Research Centre for Environment and Health (GSF) in Munich. He has longstanding expertise in neural development and molecular neurogenetics. He provides important advice in the establishment of animal models of depression disorders and generates knock-out animals for Affectis' targets.

### **Prof. Karl-Heinz Altmann**

Prof. Altmann is head of Pharmaceutical Biology at the Department of Chemistry and Applied Biosciences of the Swiss Federal Institute of Technology in Zurich. Previously, he worked for over 10 year at Novartis where he became Global Head of Chemistry at Novartis' Institutes of Biomedical Research. Prof. Altmann contributes vital counsel on chemistry, pharmacological profiling and the identification of new drug candidates.

### **Prof. Hugo Kubinyi**

Prof. Kubinyi has had a distinguished career that began at Knoll AG, and later at BASF AG, where he was responsible for molecular modelling, X-ray crystallography, and combinatorial chemistry. He is Professor of Pharmaceutical Chemistry at the University of Heidelberg. Prof. Kubinyi provides essential knowledge to Affectis regarding drug design, chemical optimisation of lead structures and SAR.

### **Prof. Walter Stühmer**

Prof. Stühmer is Director of Molecular Biology of Neuronal Signals at the Max-Planck Institute for Experimental Medicine. Prof. Stühmer supplies Affectis with valuable insight into neural signalling, ion channels, and electrophysiology.